54 completed, 26 terminated, 24 recruiting, 22 active not recruiting. 154 Phase 2, 38 Phase 1, 11 Phase 3.
Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder Tocilizumab, Placebo, Whole-Body Hyperthermia - Major Depressive Disorder | Phase 2 | Suspended | Massachusetts General Hospital | 35 | 2026-12-01 | 2025-11-13 |
| Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy - Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss | Phase 1 / Phase 2 | Not yet recruiting | VA Office of Research and Development | 43 | 2026-11-01 | 2026-10-30 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-10-30 | 2026-10-15 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE Tociliuzumab, Placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Oslo University Hospital | 156 | 2026-09-21 | 2026-10-13 |
| Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma Atezolizumab, Bevacizumab, Tocilizumab - Hepatocellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | CHA University | 51 | 2026-09-01 | 2026-08-19 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Tocilizumab, Baricitinib, Anakinra - Sepsis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2000 | 2026-07-09 | 2026-10-20 |
| Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS) Tocilizumab, Normal Saline (0.9% NaCl) - Treatment-Resistant Major Depressive Disorder | Phase 2 | Not yet recruiting | Hospital de Clinicas de Porto Alegre | 32 | 2026-07-01 | 2026-05-15 |
| A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma Ramantamig, Tocilizumab, Placebo - Multiple Myeloma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 230 | 2026-06-30 | 2026-10-01 |
| Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis Tocilizumab - Granulomatous Lobular Mastitis, Granulomatous Mastitis | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 31 | 2026-06-01 | 2026-05-19 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-10-30 |
| Tocilizumab in Chronic Inflammatory CPPD Disease Tocilizumab, Placebo - Calcium Pyrophosphate Deposition Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2026-04-01 | 2026-01-14 |
| Neutralizing Interleukin (IL)-6 Tocilizumab - Major Depressive Disorder | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 60 | 2026-03-26 | 2026-04-29 |
| Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis Tocilizumab, Discontinue Tocilizumab - Giant Cell Arteritis (GCA) | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 78 | 2026-01-05 | 2026-08-10 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis Methotrexate (MTX), Azathioprine (AZA), Adalimumab - Relapsing Polychondritis | Phase 2 | Recruiting | University of Pennsylvania | 20 | 2025-11-11 | 2026-09-02 |
| Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study Tocilizumab (Actemra®), Dexamethasone - Acute Hypoxemic Respiratory Failure | Phase 2 | Recruiting | Lorenzo delSorbo | 60 | 2025-10-20 | 2026-10-09 |
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2025-09-10 | 2026-09-08 |
| Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Tocilizumab, Prednisone - Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 102 | 2024-07-09 | 2026-01-08 |
Showing 20 of 154. Sign in to see all of them.
COVID-19 (12) · Arthritis, Rheumatoid (9) · Inflammation (7) · Giant Cell Arteritis (6) · Lymphoma, Non-Hodgkin (6) · Multiple Myeloma (6) · Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (4) · Coronavirus Infections (4) · Cytokine Release Syndrome (4) · Hematologic Neoplasms (4) · Behcet Syndrome (3) · Depressive Disorder, Major (3) · Leukemia (3) · Lymphoma, B-Cell (3)
Hoffmann-La Roche (22) · Assistance Publique - Hôpitaux de Paris (8) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Oslo University Hospital (4) · Insel Gruppe AG, University Hospital Bern (3) · NYU Langone Health (3) · National Cancer Institute (NCI) (3) · University of Chicago (3) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Herlev Hospital (2) · M.D. Anderson Cancer Center (2) · Medical College of Wisconsin (2) · Memorial Sloan Kettering Cancer Center (2) · Merck Sharp & Dohme LLC (2) · Peking Union Medical College Hospital (2)
United States (74) · France (26) · Spain (25) · China (15) · Denmark (15) · Australia (13) · United Kingdom (13) · Germany (12) · Italy (12) · South Korea (12) · Israel (11) · Canada (10) · Belgium (9) · Poland (8) · Netherlands (7)
Fu-Dong Shi, MD,PhD (2) · William R Drobyski, MD (2) · Alain Algazi, MD (1) · Alexandra Gomez Arteaga, MD (1) · Anders Opdahl, MD, PhD (1) · Ann-Cathrine Dunvald, MD (1) · Anne Hege Aamodt (1) · Apostolos Armaganidis, MD, PhD (1) · Benigno Rodriguez, MD (1) · Boglarka Gyurkocza, MD (1)
PMID 37328287, PMID 42836590, PMID 24641941, PMID 25456364, PMID 26216383, PMID 26952547, PMID 27318038, PMID 27629486, PMID 28528519, PMID 29226797, PMID 29351985, PMID 29471416, PMID 29961572, PMID 29961816, PMID 30258647, PMID 30518502, PMID 31673391, PMID 32276276, PMID 32333897, PMID 33031955, PMID 33035333, PMID 33042579, PMID 33043164, PMID 33080005, PMID 33080017, PMID 33081828, PMID 33087150, PMID 33201228, PMID 33208345, PMID 33210302, PMID 33307107, PMID 33331082, PMID 33334730, PMID 33545397, PMID 33585521, PMID 33739857, PMID 33745292, PMID 33858620, PMID 34028504, PMID 34075589, PMID 34117737, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 34588193, PMID 34612846, PMID 34747368, PMID 34893603, PMID 34941996
2023 (5), 2016 (4), 2017 (4), 2019 (4), 2018 (3), 2025 (3), 2008 (2), 2014 (1), 2015 (1), K08HL143189 (1), P30CA008748 (1), P30CA015704 (1), U01AI136816 (1), U10CA180868 (1)